Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Reports from K. Deng and colleagues advance knowledge in vaccines
June 25th, 2008
According to a study from the United States, "QS-7-Api is an exceedingly potent immuno-adjuvant isolated from the bark of Quillaja saponaria. It is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccine clinical trials." "Tedious isolation/purification protocols and uncertainty in its structural constitution have hindered the clinical development of QS-7. A chemical Synthesis of QS-7-Api is described, providing structural verification of the adjuvant," wrote K. Deng and colleagues. The researchers concluded: "A novel semisynthetic sequence to QS-7-Api has also been...
Source: Vaccine Weekly (2008-06-25)
|
